Skip to main content Skip to search Skip to main navigation

EMA: Update of the GACP Guideline Published

The guideline on Good Agricultural and Collection Practice (GACP) for herbal starting materials has been in place since 2006 to ensure consistent quality of herbal substances. The newly released Revision 1 updates the document to current standards, reflecting developments over the past decade such as the growing use of indoor cultivation technologies and published legal interpretations. In addition, Annex 1 introduces specific requirements for indoor cultivation practices.

Indoor cultivation facilities should contain adequate systems for air, climate and humidity control, light, water treatment, ventilation and air filtration systems. They are designed to:

  • Control access to personnel;
  • Minimise potential contamination;
  • Facilitate cleaning, maintenance and other operations;
  • Be impermeable to cleaning and disinfecting agents.

For documentation, the new Annex 1 stipulates:

  • Documentation of all relevant conditions, materials, and processes
  • Batch-specific acceptance criteria for cultivation & production
  • SOP-based document management including retention rules
  • Product specifications per batch defined and recorded
  • Cleaning activities documented in batch records/logbooks
  • Daily digital records of critical process parameters for indoor cultivation

Regarding crop maintenance and plant protection, Annex 1 stipulates:

  • Written procedures for material receipt, storage, handling, sampling, approval/rejection
  • Validation of processes, cleaning, and responsibilities documented
  • Calibration of all cultivation equipment per schedule
  • Material approval before each new cultivation cycle by QA
  • Indoor cultivation: Identify critical quality attributes (CQA) & process parameters (CPP)
  • Define in-process criteria and controls
  • Standardize cultivation process
  • Complete qualification of critical equipment and supporting systems

Source:

EMA: Good agricultural and collection practice for starting materials of herbal origin - Scientific guideline


Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

FDA: Draft Guidance on Responding to Form 483 Observations

FDA: Draft Guidance on Responding to Form 483 Observations

The US Food and Drug Administration (FDA) has issued a draft guidance on responding to Form FDA-483 observations following drug CGMP inspections. The document provides recommendations on how manufacturers should structure their responses and what information they should include.
Read more
Which Quality and Process Parameters must Typically be Taken into Account During Process Validation for Terminally Sterilized Products?

Which Quality and Process Parameters must Typically be Taken into Account During Process Validation for Terminally Sterilized Products?

Here's the answer:
Read more
Veterinary GMP 2026: The New Regulatory Framework

Veterinary GMP 2026: The New Regulatory Framework

Implementing Regulations (EU) 2025/2091 and 2025/2154 consolidate the GMP requirements for veterinary medicinal products into a distinct and legally binding framework for the first time. While establishing regulatory independence for the veterinary sector, they remain substantively aligned with the EU GMP Guide.
Read more
Team-NB: Opportunities and Concerns in the MDR/IVDR Revision

Team-NB: Opportunities and Concerns in the MDR/IVDR Revision

Team-NB, the European association of medical device Notified Bodies, sees the proposed MDR and IVDR revision as an opportunity to improve efficiency, transparency and predictability in conformity assessment.
Read more
EMA: GMP Documentation for the Sterilisation of an API

EMA: GMP Documentation for the Sterilisation of an API

The EMA Q&A on the quality of medicines has been updated with a new question: “What kind of GMP documentation is required for an API manufacturer performing sterilisation of an active substance?”

Read more
EMA: New Q&A Clarify Regulatory Expectations on API Mixes

EMA: New Q&A Clarify Regulatory Expectations on API Mixes

New Q&A clarify how mixtures of active pharmaceutical ingredients (APIs) and excipients (“API mixes”) should be handled from a regulatory perspective. An API mix is defined as a mixture of an API with one or more excipients and is considered the first step in the manufacture of a finished product.
Read more
Previous
Next